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In this issue of Cancer Cell, Hu et al. report that TMPK and RNR, two key enzymes in deoxyribonucleotide
biosynthesis, co-localize to damaged DNA and produce nucleotides necessary for DNA repair while
suppressing uracil incorporation. TMPK inhibition disrupts this balance and selectively sensitizes cancer
cells to low-dose chemotherapy.An ample and properly constituted supply
of deoxyribonucleotides is required for
the successful completion of DNA replica-
tion and repair. Consequently, the cellular
enzymes responsible for nucleotide bio-
synthesis have long been recognized as
possible targets for anti-cancer drugs;
one such therapeutic is 5-fluorouracil
(5-FU). 5-FU is converted intracellularly
into toxic metabolites that are incorpo-
rated into nucleic acids and additionally
inhibit thymidylate synthase (TS), a crucial
enzyme for de novo dTTP biosynthesis
(Figure 1) (Longley et al., 2003). 5-FU has
been used in the clinic for over 50 years
and is still being used for the treatment
of colorectal and other cancers. However,
5-FU treatment has toxic side-effects,
and its use is further limited by the occur-
rence of resistance. In this issue ofCancer
Cell, Hu et al. (2012) describe exciting
findings that identify thymidylate kinase
(TMPK), another key player in thymidine
nucleotide biosynthesis, as a promising
target among the nucleotide biosynthetic
machinery by virtue of its newly dis-
covered role in generating dTDP for DNA
repair directly at sites of DNA damage.
Of the four classical deoxyribonucleo-
tides, thymidine is distinguished by both
its metabolic regulation and the way it is
utilized. Thymidine is the only nonessential
deoxyribonucleotide for DNA synthesis, as
DNA polymerases typically fail to distin-
guish between dTTP and dUTP during
DNA replication and repair and can incor-
porate dUTP into DNA when dTTP is
limiting. Furthermore, while the synthesis
of cytosineandpurinenucleosides through
de novo and salvage pathways occurs in
the cytoplasm, the salvage and folate-
dependent de novo synthesis of thymidy-
late, catalyzed by thymidine kinase andTS respectively, occurs in the nucleus at
sites of DNA synthesis (Anderson et al.,
2012; Chen et al., 2010). Cellular dTTP
pools are maintained at very low levels,
and both pool depletion and expansion
affect DNA integrity and human health
(Samsonoff etal., 1997).There is increasing
evidence that dTTP is synthesized ‘‘on-site
and on-demand’’, and loss of the capacity
tosynthesizedTTP results indUaccumula-
tion in DNA, causing genomic instability
through futile cycles of DNA synthesis
and repair (Blount et al., 1997).
Previous reports indicated that targeting
dTTP production through TMPK depletion
sensitizes cells to double strand DNA
breaks (DSB) but, importantly, does not
appear to impair cell viability in theabsence
of exogenous genotoxins (Hu and Chang,
2008). The present study extends those
intriguing observations with the finding
that TMPK knockdown leads to increased
and persistent DNA lesions following treat-
ment of cells with the clastogen doxoru-
bicin. These effects were associated
with increased uracil content in DNA and
could be countered by overexpression of
dUTPase, the enzyme that removes dUTP
from the nucleotide pool.
The production of dUTP requires ribo-
nucleotide reductase (RNR), a heteromul-
timer composed of large (R1) and small
(R2) subunits that reduces NDPs to form
dNDPs. The subcellular localization of
mammalian RNR proteins has been a
matter of debate (Pontarin et al., 2008),
although recent evidence suggests that
at least some RNR complexes localize to
sites of DNA damage in the nucleus,
where they can contribute to nucleotide
production for DNA repair (Niida et al.,
2010). Interestingly, the faulty DSB repair
following TMPK knockdown could beCancer Crescued by disrupting RNR recruitment
to DNA lesions, and additional experi-
mental manipulation of RNR expression
established RNR levels as a critical deter-
minant of DSB repair proficiency following
TMPK impairment. The authors proceed
to show that TMPK, like RNR, is present
in the nucleus at sites of DNA damage.
The convergence of these pathways
where DNA repair is occurring provides
new insights into mechanisms of dUTP
synthesis and incorporation into DNA
during DSB repair. TMPK is essential for
dTDP synthesis from both the de novo
and salvage thymidylate synthesis path-
ways, whereas RNR generates dUDP in
the process of producing dNDPs needed
for DNA replication and repair, raising
the possibility of coordinated regulation
of dTDP and dUDP levels in the nucleus
at sites of DNA damage.
Taken together, the results point toward
a model (Figure 1) in which the balanced
activity of TMPK, RNR, and other factors
creates a local environment with a low
ratio of dUTP to dTTP, limiting dUTP
incorporation during DNA repair under
normal circumstances. When this regula-
tory network is perturbed by inhibition of
TMPK, dTTP levels decrease, leading to
increased uracil incorporation during
the DNA synthesis step of homologous
recombinational repair. This results in an
unproductive and ultimately lethal cycle
of events in which the incorporated uracils
are targeted for excision from the DNA,
and the region is resynthesized under
the same unfavorable nucleotide pool
conditions with a high dUTP to dTTP ratio.
The translation of these findings to
cancer therapy seems promising but
remains to be proven. Inhibition of TS by
5-FU treatment is cytotoxic to both normalell 22, July 10, 2012 ª2012 Elsevier Inc. 3
Figure 1. TMPK Co-Localizes with RNR at DNA Repair Sites to Limit Uracil Incorporation
during DNA Synthesis
(A) Under normal conditions, a low dUTP:dTTP ratio is maintained in part through the breakdown of dUTP
by dUTPase (dotted arrow) and TMPK-dependent dTTP biosynthesis.
(B) When TMPK is inhibited, such as by the small molecule YMU1, dTTP levels drop, resulting in a high
dUTP:dTTP ratio that promotes uracil incorporation into DNA. Uracils in DNA are then targeted by uracil
DNA glycosylase and excised, leading to futile repair cycles and DNA breakage (not shown).
RNR, ribonucleotide reductase; TMPK, thymidylate kinase; TS, thymidylate synthase.
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atedwith the incorporation of both dU and
5FdU into DNA. The authors propose that
TMPK may be a more desirable target
for specifically sensitizing tumor cells as
compared to established therapeutic
approaches directed against TS and the
de novo thymidylate synthesis pathway
without specificity for transformed cells
(Longley et al., 2003). Theauthors propose
that a cancer cell’s Achilles heel is its
elevated R2/TMPK ratio, leading to an
increased dependence of cancer cells on
TMPK activity to prevent uracil misincor-
poration in DNA. Moreover, R2 levels
increase after DNA damage, such as that
caused by doxorubicin and other chemo-
therapeutics, in part through a recently
identified mechanism involving Cyclin F
(D’Angiolella et al., 2012), potentially
further tilting the dUTP:dTTP ratio at DNA4 Cancer Cell 22, July 10, 2012 ª2012 Elsevidamage sites in an unfavorable direction
when TMPK is inhibited. These effects
may be compounded in cancer cells
because they often have cell cycle check-
point defects and an increased S-phase
fraction, which could contribute to high
RNR activity aswell asmore opportunities
for usage of homologous recombination
for DNA repair.
The development of their lead com-
pound, YMU1, offers some hope that
this strategy could be realized. This selec-
tive, cell permeable TMPK inhibitor, iden-
tified by screening a small molecule
library, has an IC50 of 0.6 mM. Similar to
the effect of TMPK knockdown, treatment
of cells with YMU1 alone does not signifi-
cantly affect cell proliferation or cause
cytotoxicity. It remains unclear why cells
can tolerate TMPK inhibition in the ab-
sence of extrinsic stresses given theer Inc.integral role of TMPK in dTDP production.
The authors speculate that cells may
produce variant isoforms of TMPK that
could account for residual dTDP produc-
tion after TMPK inhibition. Clearly, addi-
tional genetic and biochemical analyses
are called for as TMPK continues to be
explored as a drug target. Nevertheless,
YMU1 sensitizes cultured tumor cells to
low dose doxorubicin treatment, resulting
in increased DNA damage and enhanced
cell killing. Initial studies in a tumor xeno-
graft mouse model further suggest that
YMU1 in combination with doxorubicin
suppresses tumor growth in vivo. Even
before TMPK inhibitors are further evalu-
ated for potential use in patients, the find-
ings of Hu et al. (2012) suggest that moni-
toring the relative protein levels of R2 and
TMPK in cancers could be predictive of
chemosensitivity. While it remains to be
seen whether this will be the case, the
new focus on TMPK raised by this work
has the potential to extend the long
history of using the knowledge of the
fundamentals of nucleotide metabolism
for therapeutic benefit.
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